Market Cap | 10.54B | P/E | 21.19 | EPS this Y | 3.10% | Ern Qtrly Grth | -0.20% |
Income | 474.62M | Forward P/E | 17.18 | EPS next Y | 12.80% | 50D Avg Chg | - |
Sales | 4.13B | PEG | 2.63 | EPS past 5Y | 14.18% | 200D Avg Chg | -4.00% |
Dividend | N/A | Price/Book | 3.39 | EPS next 5Y | 9.19% | 52W High Chg | -21.00% |
Recommedations | 2.10 | Quick Ratio | 1.00 | Shares Outstanding | 51.35M | 52W Low Chg | 14.00% |
Insider Own | 1.05% | ROA | 5.19% | Shares Float | 50.72M | Beta | 1.39 |
Inst Own | 103.07% | ROE | 14.38% | Shares Shorted/Prior | 1.59M/1.92M | Price | 206.01 |
Gross Margin | 37.03% | Profit Margin | 11.49% | Avg. Volume | 483,998 | Target Price | 266.34 |
Oper. Margin | 14.52% | Earnings Date | May 9 | Volume | 373,835 | Change | -1.58% |
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Argus Research | Buy | Mar 18, 24 |
Evercore ISI Group | Outperform | Feb 15, 24 |
UBS | Buy | Feb 15, 24 |
Citigroup | Neutral | Feb 15, 24 |
Baird | Outperform | Feb 15, 24 |
JP Morgan | Overweight | Feb 15, 24 |
Guggenheim | Neutral | Feb 15, 24 |
JP Morgan | Overweight | Dec 20, 23 |
Citigroup | Neutral | Dec 11, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Girshick Birgit | Corporate Executive.. Corporate Executive VP & COO | Jan 10 | Option | 144.67 | 5,916 | 855,868 | 50,365 | 01/31/24 |
FOSTER JAMES C | Chairman, President.. Chairman, President and CEO | Jan 29 | Option | 144.67 | 17,436 | 2,522,466 | 227,827 | 01/31/24 |
LaPlume Joseph W | EVP, Corp Strategy &.. EVP, Corp Strategy & Develop | May 15 | Sell | 190.39 | 345 | 65,685 | 24,026 | 05/16/23 |
LaPlume Joseph W | EVP, Corp Strategy &.. EVP, Corp Strategy & Develop | May 12 | Sell | 193.55 | 959 | 185,614 | 24,371 | 05/15/23 |
MASSARO GEORGE | Director Director | May 11 | Sell | 193.43 | 288 | 55,708 | 4,964 | 05/15/23 |
Parisotto Shannon M | CEVP, Disc & Safety.. CEVP, Disc & Safety Assessment | Feb 16 | Sell | 252.49 | 4,558 | 1,150,849 | 6,010 | 02/21/23 |
Parisotto Shannon M | CEVP, Disc & Safety.. CEVP, Disc & Safety Assessment | Feb 16 | Option | 109.34 | 4,558 | 498,372 | 10,568 | 02/21/23 |
Girshick Birgit | Corporate Executive.. Corporate Executive VP & COO | Feb 16 | Sell | 251.9 | 3,205 | 807,340 | 41,038 | 02/17/23 |
Girshick Birgit | Corporate Executive.. Corporate Executive VP & COO | Feb 16 | Option | 109.34 | 3,205 | 350,435 | 44,243 | 02/17/23 |
LaPlume Joseph W | EVP, Corp Strategy &.. EVP, Corp Strategy & Develop | Nov 04 | Sell | 216.36 | 534 | 115,536 | 20,232 | 11/07/22 |
LaPlume Joseph W | EVP, Corp Strategy &.. EVP, Corp Strategy & Develop | Jul 06 | Sell | 226.13 | 200 | 45,226 | 20,766 | 08/08/22 |
LaPlume Joseph W | EVP, Corp Strategy &.. EVP, Corp Strategy & Develop | Feb 23 | Sell | 292.75 | 395 | 115,636 | 19,852 | 02/24/22 |
FOSTER JAMES C | Chairman, President.. Chairman, President and CEO | Feb 22 | Option | 144.67 | 17,436 | 2,522,466 | 234,228 | 02/23/22 |
FOSTER JAMES C | Chairman, President.. Chairman, President and CEO | Feb 22 | Sell | 289.37 | 17,436 | 5,045,455 | 216,792 | 02/23/22 |
Girshick Birgit | Corporate Executive.. Corporate Executive VP | Sep 15 | Sell | 441.61 | 2,425 | 1,070,904 | 27,602 | 09/15/21 |
MASSARO GEORGE | Director Director | Sep 01 | Sell | 442.57 | 2,539 | 1,123,685 | 4,855 | 09/01/21 |
MASSARO GEORGE | Director Director | Sep 01 | Option | 164.24 | 2,539 | 417,005 | 7,394 | 09/01/21 |
Creamer Victoria L | EVP & Chief People O.. EVP & Chief People Officer | Aug 17 | Sell | 415.24 | 6,917 | 2,872,215 | 6,386 | 08/17/21 |
Creamer Victoria L | EVP & Chief People O.. EVP & Chief People Officer | Aug 17 | Option | 149.49 | 6,917 | 1,034,022 | 13,303 | 08/17/21 |
Knell Michael Gunnar | CSVP&Chief Accountin.. CSVP&Chief Accounting Officer | Jun 07 | Option | 144.56 | 1,527 | 220,743 | 5,757 | 06/07/21 |
FOSTER JAMES C | Chairman, President.. Chairman, President and CEO | May 10 | Sell | 343.64 | 7,500 | 2,577,300 | 216,072 | 05/10/21 |
FOSTER JAMES C | Chairman, President.. Chairman, President and CEO | Feb 25 | Option | 88.05 | 24,009 | 2,113,992 | 245,160 | 02/25/21 |
FOSTER JAMES C | Chairman, President.. Chairman, President and CEO | Feb 25 | Sell | 284.46 | 24,009 | 6,829,600 | 221,151 | 02/25/21 |
Girshick Birgit | Corporate Executive.. Corporate Executive VP | Feb 23 | Option | 73.7 | 1,675 | 123,448 | 31,680 | 02/23/21 |
Girshick Birgit | Corporate Executive.. Corporate Executive VP | Feb 23 | Sell | 293.92 | 1,675 | 492,316 | 30,005 | 02/23/21 |